For Health Care Professionals

There may be hope for your patients with neurobehavioral disinhibition including aggression, agitation, and irritability resulting from a traumatic brain injury (TBI).

If you are a physician and want to learn more about this TBI Clinical Research Study, please complete the form.

About Traumatic
Brain Injury (TBI)

Advances in medical understanding of the lasting impact of a traumatic brain injury (TBI) continue to come to light as scientists and medical researchers uncover new information about how the human brain heals. There are currently no FDA-approved medications specifically for behavioral symptoms resulting from a TBI.

About a New Research Study Enrolling Patients

Avanir Pharmaceuticals, Inc. has launched a Phase 2 clinical research study designed to assess the efficacy, safety and tolerability of an investigational drug, AVP-786, for the potential treatment of neurobehavioral disinhibition including aggression, agitation, and irritability associated with a traumatic brain injury (TBI). AVP-786 is an oral capsule, which contains the active ingredients deudextromethorphan hydrobromide and quinidine sulfate. For the purposes of this research study, it is administered twice daily by the participant or their reliable study partner. Participation is expected to last a total of 17 weeks.

All study-related visits, tests, and study drugs will be provided at no-cost to the participant. In addition, compensation for completed study visits may be provided to them. You, of course, will continue to be their physician for non-study related medical needs.

Who is Eligible?

To pre-qualify, potential participants must:

  • Be 18 to 75 years of age.
  • Meet diagnostic criteria for a TBI as defined per protocol (mild, moderate, and severe). 
  • Have no additional head trauma in the past 6 months.
  • Have a history of aggression, agitation, or irritability that was not present before the TBI.
  • Have a reliable study partner.
  • Be stable with use of other therapies for 3 months:
    • Nondrug therapies (e.g. acupuncture, PT, etc.).
    • Hypnotics at bedtime for insomnia.
    • Antipsychotic or depression medications.
    • Herbal supplements.
    • Marijuana.

We Want to Hear from Your Patients

If you have a potential study participant that may be a candidate for this clinical research study, have them visit this page.

* This page is intended for healthcare professionals only. If you are a patient, please visit another page.

Your choice regarding cookies on this site – We use cookies to optimize site functionality and give you the best experience.  Necessary cookies enable core functionality. The website cannot function properly without these cookies and can only be disabled by changing your browser preferences. For more detailed information on the cookies we use, please check our Privacy Policy. By continuing to access this website you are giving us consent to collect cookies.